187 related articles for article (PubMed ID: 33323024)
1. Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.
Papasavvas E; Azzoni L; Pagliuzza A; Abdel-Mohsen M; Ross BN; Fair M; Howell BJ; Hazuda DJ; Chomont N; Li Q; Mounzer K; Kostman JR; Tebas P; Montaner LJ
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):433-443. PubMed ID: 33323024
[TBL] [Abstract][Full Text] [Related]
2. NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.
Papasavvas E; Azzoni L; Kossenkov AV; Dawany N; Morales KH; Fair M; Ross BN; Lynn K; Mackiewicz A; Mounzer K; Tebas P; Jacobson JM; Kostman JR; Showe L; Montaner LJ
J Immunol; 2019 Aug; 203(3):705-717. PubMed ID: 31253727
[TBL] [Abstract][Full Text] [Related]
3. Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.
Papasavvas E; Azzoni L; Ross BN; Fair M; Howell BJ; Hazuda DJ; Mounzer K; Kostman JR; Tebas P; Montaner LJ
AIDS; 2021 Oct; 35(12):2051-2054. PubMed ID: 34049356
[TBL] [Abstract][Full Text] [Related]
4. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.
Azzoni L; Foulkes AS; Papasavvas E; Mexas AM; Lynn KM; Mounzer K; Tebas P; Jacobson JM; Frank I; Busch MP; Deeks SG; Carrington M; O'Doherty U; Kostman J; Montaner LJ
J Infect Dis; 2013 Jan; 207(2):213-22. PubMed ID: 23105144
[TBL] [Abstract][Full Text] [Related]
5. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
6. Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
Hua S; Vigano S; Tse S; Zhengyu O; Harrington S; Negron J; Garcia-Broncano P; Marchetti G; Genebat M; Leal M; Resino S; Ruiz-Mateos E; Lichterfeld M; Yu XG
Clin Infect Dis; 2018 Jun; 66(12):1910-1917. PubMed ID: 29272392
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
9. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients.
Brockmeyer NH; Poffhoff A; Bader A; Hochdorfer B; Schlottmann R; Rasokat H; Altmeyer P; Kreuter A
Eur J Med Res; 2006 Jan; 11(1):27-32. PubMed ID: 16504957
[TBL] [Abstract][Full Text] [Related]
10. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.
Asmuth DM; Murphy RL; Rosenkranz SL; Lertora JJ; Kottilil S; Cramer Y; Chan ES; Schooley RT; Rinaldo CR; Thielman N; Li XD; Wahl SM; Shore J; Janik J; Lempicki RA; Simpson Y; Pollard RB;
J Infect Dis; 2010 Jun; 201(11):1686-96. PubMed ID: 20420510
[TBL] [Abstract][Full Text] [Related]
13. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
14. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
[TBL] [Abstract][Full Text] [Related]
15. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
16. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.
Goujard C; Emilie D; Roussillon C; Godot V; Rouzioux C; Venet A; Colin C; Pialoux G; Girard PM; Boilet V; Chaix ML; Galanaud P; Chene G;
AIDS; 2012 Sep; 26(15):1895-905. PubMed ID: 22842994
[TBL] [Abstract][Full Text] [Related]
17. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.
Adalid-Peralta L; Godot V; Colin C; Krzysiek R; Tran T; Poignard P; Venet A; Hosmalin A; Lebon P; Rouzioux C; Chene G; Emilie D;
J Leukoc Biol; 2008 Apr; 83(4):1060-7. PubMed ID: 18182457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
